Establishment of latent HIV-1 reservoirs: what do we really know?
- PMID: 30800420
- PMCID: PMC6362902
- DOI: 10.1016/S2055-6640(20)30275-2
Establishment of latent HIV-1 reservoirs: what do we really know?
Abstract
Despite our ability to suppress HIV-1 replication indefinitely in people on optimal combined antiretroviral therapy (cART), HIV-1 persists as a stably integrated and replication-competent provirus in a heterogeneous collection of long-lived cells (often referred to as 'latent reservoirs') in all individuals on treatment. Reactivation of these latent proviruses is believed to be responsible for the rebound viraemia that can be seen in nearly all people following treatment cessation. Hence, the persistence of HIV-1 in latent reservoirs remains one of the greatest challenges in current HIV cure research. Latent HIV-1 reservoirs are established early during the acute phase of the infection, possibly before the virus appears in the systemic circulation. As well as the issue of timing, we review the proposed hypotheses on the mechanisms by which this latent state is believed to be established early in the course of the infection and the effect of early initiation of cART on the size and stability of these reservoirs. We conclude that prevention of the establishment of latent HIV-1 reservoirs by even extremely early initiation of cART proves to be practically impossible. However, early treatment initiation remains one of the crucial interventions needed to achieve the ultimate goal of a functional cure for HIV-1 infection because of its ability to reduce the overall size of HIV-1 reservoirs. Together with other interventions, early cART initiation may thus eventually lead to a state of better control over the residual amount of virus in the body, allowing people to stay off treatment for prolonged periods of time.
Similar articles
-
Finding a cure for HIV: will it ever be achievable?J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4. J Int AIDS Soc. 2011. PMID: 21255462 Free PMC article.
-
The role of integration and clonal expansion in HIV infection: live long and prosper.Retrovirology. 2018 Oct 23;15(1):71. doi: 10.1186/s12977-018-0448-8. Retrovirology. 2018. PMID: 30352600 Free PMC article. Review.
-
Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus.Biochem Biophys Res Commun. 2015 Apr 3;459(2):288-293. doi: 10.1016/j.bbrc.2015.02.102. Epub 2015 Feb 26. Biochem Biophys Res Commun. 2015. PMID: 25727021
-
Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.Viruses. 2021 Feb 21;13(2):335. doi: 10.3390/v13020335. Viruses. 2021. PMID: 33670027 Free PMC article. Review.
-
Insights Into Persistent HIV-1 Infection and Functional Cure: Novel Capabilities and Strategies.Front Microbiol. 2022 Apr 27;13:862270. doi: 10.3389/fmicb.2022.862270. eCollection 2022. Front Microbiol. 2022. PMID: 35572626 Free PMC article. Review.
Cited by
-
HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies.Cells. 2021 Feb 23;10(2):475. doi: 10.3390/cells10020475. Cells. 2021. PMID: 33672138 Free PMC article. Review.
-
MicroRNAs and long non-coding RNAs during transcriptional regulation and latency of HIV and HTLV.Retrovirology. 2024 Feb 29;21(1):5. doi: 10.1186/s12977-024-00637-y. Retrovirology. 2024. PMID: 38424561 Free PMC article. Review.
-
SERPIN-Derived Small Peptide (SP16) as a Potential Therapeutic Agent against HIV-Induced Inflammatory Molecules and Viral Replication in Cells of the Central Nervous System.Cells. 2023 Feb 15;12(4):632. doi: 10.3390/cells12040632. Cells. 2023. PMID: 36831299 Free PMC article.
-
Off-Target Effect of Activation of NF-κB by HIV Latency Reversal Agents on Transposable Elements Expression.Viruses. 2022 Jul 20;14(7):1571. doi: 10.3390/v14071571. Viruses. 2022. PMID: 35891551 Free PMC article.
-
Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.J Virol. 2022 Mar 9;96(5):e0173021. doi: 10.1128/JVI.01730-21. Epub 2022 Jan 12. J Virol. 2022. PMID: 35019724 Free PMC article.
References
-
- Hütter G, Nowak D, Mossner M et al. . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009. 360: 692– 698. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials